help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 10, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1345
A more recent version of this article appeared on January 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/1/28    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hackshaw, A.
Right arrow Articles by Franklyn, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hackshaw, A.
Right arrow Articles by Franklyn, J. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Thyroid Cancer

Submitted on June 21, 2006
Accepted on September 29, 2006

131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review

Allan Hackshaw*, Clive Harmer, Ujjal Mallick, Masud Haq, and Jayne A. Franklyn

Allan Hackshaw, Deputy Director, Senior Lecturer in Epidemiology & Medical Statistics, Cancer Research UK & UCL Cancer Trials Centre, University College London, Stephenson House, 158-160 North Gower Street, London NW1 2, Telephone: +44 20 7679 8008, Fax: +44 20 7679 8001, E-mail: ah@ctc.ucl.ac.uk. Clive Harmer, Formerly Thyroid Cancer Unit, Royal Marsden Hospital, London; Ujjal Mallick, Newcastle General Hospital, Newcastle; Masud Haq, St Georges Hospital, London; Jayne A. Franklyn, Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham

* To whom correspondence should be addressed. E-mail: ah{at}ctc.ucl.ac.uk.

Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly performed in the management of patients with differentiated thyroid cancer. While many centers administer an activity of 100 mCi, there is uncertainty over using a lower activity.

Objective: A systematic review of the published literature was used to compare the success rates of remnant ablation using about 30 mCi with around 100 mCi (1.1 vs. 3.7 GBq).

Data sources: Medline and Embase 1966 to March 2006.

Study selection: All studies that reported rates of successful ablation associated with about 30 or around 100 mCi of radioiodine.

Data extraction: Studies were based on reviews of patient case notes (n = 41), prospective cohorts (n = 12) and randomized trials (n = 6). We obtained the success of thyroid remnant ablation according to different administered activities of radioiodine. Where a study reported on two or more activities, the risk ratio of having a successful ablation (about 30 vs. around 100 mCi) was calculated and combined in a meta-analysis.

Data synthesis: Observational studies confirmed the high ablation success rate (approximately 80%) using around 100 mCi, though 22% of studies reported a rate ≥90%. The pooled ablation success rate in these studies was 10% lower using 30 mCi compared with 100 mCi (95% CI 3 to 17%, P = 0.01). The meta-analysis of the randomized trials produced equivocal results. For example, the rate of successful ablation in patients given 30 mCi was 8% lower compared with 100 mCi (95% CI 29% lower or up to 20% greater, P = 0.58), consistent with there being no difference or that 30 mCi is much less effective.

Conclusions: From the published data, it is not possible to reliably determine whether ablation success rates using 30 mCi are similar to using 100 mCi. Large randomized trials are needed to resolve the issue and guide clinical practice.


Key words: Thyroid cancer • thyroid remnant ablation • radioiodine administered activity • systematic review




This article has been cited by other articles:


Home page
haematolHome page
D. Focosi, S. Galimberti, and M. Petrini
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases
Haematologica, September 1, 2007; 92(9): e96 - e97.
[Full Text] [PDF]


Home page
Clin Med ResHome page
S. A.R. Doi, N. J. Woodhouse, L. Thalib, and A. Onitilo
Ablation of the Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: A Meta-Analysis Revisited
Clin. Med. Res., June 1, 2007; 5(2): 87 - 90.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society